Exploring T-cell bispecific antibodies in gynecologic malignancy., PMID:40502816
Exploring T-cell bispecific antibodies in gynecologic malignancy., PMID:40502816
Synergistic Signal Amplification via Weak Value Amplification Effect and Sandwich Structure for Highly Sensitive and Specific Real-Time Detection of CA125., PMID:40422007
Synergistic Signal Amplification via Weak Value Amplification Effect and Sandwich Structure for Highly Sensitive and Specific Real-Time Detection of CA125., PMID:40422007
Mapping the Binding Sites of CA125-Specific Antibodies on a Revised Molecular Model of MUC16., PMID:40361385
Mapping the Binding Sites of CA125-Specific Antibodies on a Revised Molecular Model of MUC16., PMID:40361385
Humanized Anti-MUC16 Antibody-Conjugated Contrast Agents for Magnetic Resonance Imaging of Pancreatic Cancer., PMID:40149293
Humanized Anti-MUC16 Antibody-Conjugated Contrast Agents for Magnetic Resonance Imaging of Pancreatic Cancer., PMID:40149293
A bispecific anti-MUC16/anti-death receptor 5 antibody achieves effective and tumor-selective death receptor 5-mediated tumor regression., PMID:40121208
A bispecific anti-MUC16/anti-death receptor 5 antibody achieves effective and tumor-selective death receptor 5-mediated tumor regression., PMID:40121208
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer., PMID:40081941
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer., PMID:40081941
Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach., PMID:39935174
Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach., PMID:39935174
MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer., PMID:39863644
MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer., PMID:39863644
An electrochemical immunosensor for carbohydrate antigen CA125 based on electroactive COFs as a signal probe., PMID:39778493
An electrochemical immunosensor for carbohydrate antigen CA125 based on electroactive COFs as a signal probe., PMID:39778493
Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer., PMID:39652449
Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer., PMID:39652449
Pretargeted alpha therapy in MUC16-positive high-grade serous ovarian cancer., PMID:39615062
Pretargeted alpha therapy in MUC16-positive high-grade serous ovarian cancer., PMID:39615062
MUC16 Retention after Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma., PMID:39456534
MUC16 Retention after Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma., PMID:39456534
Detection of MUC1+/MUC2 and MUC5AC- Membrane-Associated Mucins in the Intraepithelial Surface Mucous Cells of the Developing Rabbit Esophagus., PMID:39396509
Detection of MUC1+/MUC2 and MUC5AC- Membrane-Associated Mucins in the Intraepithelial Surface Mucous Cells of the Developing Rabbit Esophagus., PMID:39396509
Genome-wide association studies of COVID-19 vaccine seroconversion and breakthrough outcomes in UK Biobank., PMID:39384777
Genome-wide association studies of COVID-19 vaccine seroconversion and breakthrough outcomes in UK Biobank., PMID:39384777
ADC: a deadly killer of platinum resistant ovarian cancer., PMID:39367438
ADC: a deadly killer of platinum resistant ovarian cancer., PMID:39367438
A disposable ultrasensitive immunosensor based on MXene/NH2-CNT modified screen-printed electrode for the detection of ovarian cancer antigen CA125., PMID:39288586
A disposable ultrasensitive immunosensor based on MXene/NH2-CNT modified screen-printed electrode for the detection of ovarian cancer antigen CA125., PMID:39288586
Immunoaffinity-free chromatographic purification of ovarian cancer biomarker CA125 (MUC16) from blood serum enables mass spectrometry characterization., PMID:39177265
Immunoaffinity-free chromatographic purification of ovarian cancer biomarker CA125 (MUC16) from blood serum enables mass spectrometry characterization., PMID:39177265
Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy., PMID:39118097
Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy., PMID:39118097
Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis., PMID:39105794
Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis., PMID:39105794
Carbohydrate antigen 125 on epicardial fat and its association with local inflammation and fibrosis-related markers., PMID:38961436
Carbohydrate antigen 125 on epicardial fat and its association with local inflammation and fibrosis-related markers., PMID:38961436
Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma., PMID:38934093
Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma., PMID:38934093
An electrochemical immunosensor based on MXene-GQD/AuNPs for the detection of trace amounts of CA-125 as specific tracer of ovarian cancer., PMID:38914884
An electrochemical immunosensor based on MXene-GQD/AuNPs for the detection of trace amounts of CA-125 as specific tracer of ovarian cancer., PMID:38914884
Theranostic Capacity of a Mucin 16-targeted Antibody for Ovarian Cancer., PMID:38819265
Theranostic Capacity of a Mucin 16-targeted Antibody for Ovarian Cancer., PMID:38819265
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16., PMID:38604812
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16., PMID:38604812
Spectrally separated dual-label upconversion luminescence lateral flow assay for cancer-specific STn-glycosylation in CA125 and CA15-3., PMID:38584178
Spectrally separated dual-label upconversion luminescence lateral flow assay for cancer-specific STn-glycosylation in CA125 and CA15-3., PMID:38584178
Structural Elucidation and Prognostic Relevance of 297-11A-Sulfated Glycans in Ovarian Carcinoma., PMID:38582455
Structural Elucidation and Prognostic Relevance of 297-11A-Sulfated Glycans in Ovarian Carcinoma., PMID:38582455
Sandwich-type electrochemical immunosensing of CA125 by using nanoribbon-like Ti3C2Tx MXenes and toluidine blue/UIO-66-NH2., PMID:38578575
Sandwich-type electrochemical immunosensing of CA125 by using nanoribbon-like Ti3C2Tx MXenes and toluidine blue/UIO-66-NH2., PMID:38578575
Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer., PMID:38485271
Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer., PMID:38485271
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma., PMID:38438589
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma., PMID:38438589
GlcNAc6ST2/CHST4 Is Essential for the Synthesis of R-10G-Reactive Keratan Sulfate/Sulfated N-Acetyllactosamine Oligosaccharides in Mouse Pleural Mesothelium., PMID:38398516
GlcNAc6ST2/CHST4 Is Essential for the Synthesis of R-10G-Reactive Keratan Sulfate/Sulfated N-Acetyllactosamine Oligosaccharides in Mouse Pleural Mesothelium., PMID:38398516
Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6., PMID:38394685
Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6., PMID:38394685
Structural basis for antibody recognition of the proximal MUC16 ectodomain., PMID:38374055
Structural basis for antibody recognition of the proximal MUC16 ectodomain., PMID:38374055
Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial., PMID:38246047
Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial., PMID:38246047
Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies., PMID:38225646
Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies., PMID:38225646
Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model., PMID:38053658
Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model., PMID:38053658
MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer., PMID:37644468
MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer., PMID:37644468
Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1., PMID:37635172
Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1., PMID:37635172
Strategies for Mitigating Commercial Sensor Chip Variability with Experimental Design Controls., PMID:37571487
Strategies for Mitigating Commercial Sensor Chip Variability with Experimental Design Controls., PMID:37571487
Chimeric antibody targeting unique epitope on onco-mucin16 reduces tumor burden in pancreatic and lung malignancies., PMID:37567918
Chimeric antibody targeting unique epitope on onco-mucin16 reduces tumor burden in pancreatic and lung malignancies., PMID:37567918
Electrochemical biotool for the dual determination of epithelial mucins associated to prognosis and minimal residual disease in colorectal cancer., PMID:37499706
Electrochemical biotool for the dual determination of epithelial mucins associated to prognosis and minimal residual disease in colorectal cancer., PMID:37499706
Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies., PMID:37388728
Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies., PMID:37388728
High Sensitivity Extended Nano-Coulter Counter for Detection of Viral Particles and Extracellular Vesicles., PMID:37336762
High Sensitivity Extended Nano-Coulter Counter for Detection of Viral Particles and Extracellular Vesicles., PMID:37336762
Individual recombinant repeats of MUC16 display variable binding to CA125 antibodies., PMID:37248884
Individual recombinant repeats of MUC16 display variable binding to CA125 antibodies., PMID:37248884
Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1., PMID:37214945
Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1., PMID:37214945
NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects., PMID:37195923
NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects., PMID:37195923
Transmembrane Mucin Response in Conjunctival Epithelial Cells Exposed to Wall Shear Stresses., PMID:37047561
Transmembrane Mucin Response in Conjunctival Epithelial Cells Exposed to Wall Shear Stresses., PMID:37047561
Individual recombinant repeats of MUC16 display variable binding to CA125 antibodies., PMID:36798296
Individual recombinant repeats of MUC16 display variable binding to CA125 antibodies., PMID:36798296
Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial., PMID:36753834
Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial., PMID:36753834
Engineering of a Fully Human Anti-MUC-16 Antibody and Evaluation as a PET Imaging Agent., PMID:36559316
Engineering of a Fully Human Anti-MUC-16 Antibody and Evaluation as a PET Imaging Agent., PMID:36559316
Experimental drugs for fallopian cancer: promising agents in the clinical trials and key stumbling blocks for researchers., PMID:36537209
Experimental drugs for fallopian cancer: promising agents in the clinical trials and key stumbling blocks for researchers., PMID:36537209
For research use only. Not for human or drug use.
